Bio-Techne Corp. TECH recently launched an expanded menu of human and mouse RNAscope in situ hybridization probes to advance spatial biology research and the development of next-generation ...

Fintel reports that on February 19, 2025, Baird downgraded their outlook for Bio-Techne (NasdaqGS:TECH) from Outperform to ...

Baird R W lowered shares of Bio-Techne (NASDAQ:TECH – Free Report) from a strong-buy rating to a hold rating in a research note published on Wednesday morning,Zacks.com reports. Several other research ...

New York State Teachers Retirement System lowered its stake in shares of Bio-Techne Co. (NASDAQ:TECH – Free Report) by 0.2% ...

Bio-Techne Corporation (NASDAQ: TECH), a leading provider of innovative life science research tools, is pleased to announce the official release of GMP Transposase mRNA for the TcBuster™ non-viral ...

In the last three months, 4 analysts have published ratings on Bio-Techne (NASDAQ:TECH), offering a diverse range of perspectives from bullish to bearish. Summarizing their recent assessments ...

MINNEAPOLIS, Feb. 18, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH), a leading provider of innovative life science research tools, is pleased to announce the official release of GMP ...

Bio-Techne (TECH) announced the launch of an expanded menu of human and mouse RNAscope in situ hybridization probes to advance spatial biology research and the development of next-generation ...

近期，Bio-Techne Corp（NASDAQ:TECH）董事Amy E. Herr进行了一笔股票交易。在2025年2月14日，她以平均每股$65.96的价格出售了总值$122,690的股票。此次交易后，Herr在公司的直接持股量为1,040股。根据 InvestingPro 数据显示，该公司股票目前接近52周低点$61.16，分析师给出的目标价区间为$75至$95。